Navigation Links
Ambrx Appoints Douglas Axelrod Senior Vice President for Clinical Research and Development
Date:2/26/2008

SAN DIEGO, Feb. 26 /PRNewswire/ -- Ambrx Inc. today announced the appointment of Douglas W. Axelrod, M.D., Ph.D., as Senior Vice President for Clinical Research and Development.

Axelrod joins Ambrx after a productive career spanning nearly two decades at Procter & Gamble Pharmaceuticals. Most recently, he served as Vice President of R&D for Discovery, Early Development and Product Development where he accelerated the discovery process, improved the discovery to early development transition and led efficiencies in product development. Earlier in his career, Axelrod led the P&G Worldwide Clinical Bone group, stewarding drugs such as Didronel(TM) and Actonel(TM) through late clinical development and regulatory approvals. These drugs became among the leading osteoporosis therapies worldwide. Axelrod obtained his doctorate in the Department of Cell Biology at Baylor College of Medicine. He obtained his medical degree at the same institution, where he completed his Residency in Internal Medicine, Fellowship in Endocrinology and Metabolism and served as Visiting Scientist in the Department of Cell Biology at MD Anderson Tumor Institute.

"Doug has tremendous depth and breadth of experience in drug discovery and development and has been successful in delivering innovative medicines to patients," said Steve Kaldor, Ph.D., Ambrx's President and CEO. "He will be integral to the ongoing build out of Ambrx's development capabilities in support of our rapidly maturing pipeline of clinical and preclinical phase protein drug candidates."

Axelrod added: "I am pleased and excited to join Ambrx at this exciting stage of its development. The company has moved rapidly from proof of concept of the ReCODE(TM) technologies to the creation and development of a family of important and practical biologics-based products. I look forward to playing a role in bringing these important products to clinical reality and into the marketplace, both with our collaborators and as independent Ambrx efforts."

About Ambrx

Ambrx Inc. is a clinical stage biopharmaceutical company with a broad biologics platform that allows it to create best-in-class protein therapeutics, including improved versions of native proteins and therapeutic antibodies. Its most advanced product candidate, ARX-201, is a long-acting human growth hormone drug candidate partnered with Merck Serono that has successfully completed initial clinical trials. The company has further validated its biologics platform through substantial partnerships with Eli Lilly and Company and Merck & Co. Ambrx is advancing a robust portfolio of product opportunities spanning multiple therapeutic areas that are highly optimized for efficacy, safety, and ease of use. For additional information, call 858.875.2400 or visit http://www.ambrx.com.


'/>"/>
SOURCE Ambrx Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
2. Codexis Appoints Singapore Laboratories Managing Director
3. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
4. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
5. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
6. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
7. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
8. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
9. NeurogesX Appoints New Director to the Board
10. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
11. Premier Research Appoints Melissa Jones as Vice President, International Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Proove Biosciences, Inc ., ... the launch of the Proove Health Foundation . The Foundation is a ... the use of personalized medicine for tackling the nation’s most-pressing healthcare epidemics. As ...
(Date:4/29/2016)... ... ... Intelligent Implant Systems announced today that the two-level components for the Revolution™ Spinal ... These components expand the capabilities of the system and allow Revolution™ to be ... 2015, the company has seen significant sales growth in 1Q 2016, and the system ...
(Date:4/28/2016)... ... 28, 2016 , ... Next week on May 5 at ... technologies for tissue stem cell counting and expansion to gene-editing scientists and other ... CRISPR-based Genome Engineering in Burlington, Massachusetts. , The attention of most gene-editing scientists ...
(Date:4/27/2016)... , ... April 27, 2016 , ... The Pittcon Organizing ... 2019. Chuck has been a volunteer member of Committee since 1987. Since then, ... board of directors and treasurer and was chairman for both the program and exposition ...
Breaking Biology Technology:
(Date:3/10/2016)... --  Unisys Corporation (NYSE: UIS ) today announced ... testing its biometric identity solution at the Otay Mesa border ... identify certain non-U.S. citizens leaving the country. ... determine the efficiency and accuracy of using biometric technologies in ... until May 2016. --> the United States ...
(Date:3/3/2016)... , March 3, 2016  FlexTech, a SEMI Strategic ... of Innovation, Research & Development, Leadership in Education, and, ... is the 9 th year of the FLEXI ... companies and individuals from past years . Judging ... a pre-described set of criteria, by a panel of ...
(Date:3/1/2016)... , March 1, 2016 /PRNewswire/ ... announced the addition of the  "Global ...  report to their offering. ... the addition of the  "Global Biometric ...  report to their offering. --> ...
Breaking Biology News(10 mins):